Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of MEDI-524 (Motavizumab), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States

NCT00121108 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT00121108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00121108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of MEDI-524 (Motavizumab), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States
Lead sponsor
MedImmune LLC
Phase
Phase 3
Overall status
Completed
Start date
November 15, 2004
Completion date
December 27, 2010
Enrollment
2,127 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

healthy